Sonnet biotherapeutics completes enrollment in phase 1 study of son-1010 (il12-fhab) as a monotherapy (sb101) for the treatment of solid tumors

Son-1010 is a targeted immune activation cancer therapy designed to turn ‘cold' tumors ‘hot' topline safety data of sb101 phase 1 study expected by q4 2024 princeton, nj, sept. 18, 2024 (globe newswire) -- sonnet biotherapeutics holdings, inc. (the “company” or “sonnet”) (nasdaq: sonn), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the completion of enrollment and initiation of dosing in its phase 1 sb101 clinical trial of son-1010 (il12-fhab) in adult patients with advanced solid tumors.
SONN Ratings Summary
SONN Quant Ranking